PCP
EW icon

Perbak Capital Partners’s Edwards Lifesciences EW Stock Holding History

Perbak Capital Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$600K Buy
+7,497
New +$618K 0.15% 161
2025
Q4 		– Sell
-8,238
Closed -$641K – 258
2025
Q3 		$641K Buy
+8,238
New +$644K 0.11% 199

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Perbak Capital Partners's EW Position: Q1 2026 in Review

Perbak Capital Partners opened a new position in Edwards Lifesciences (EW) in Q1 2026: 7,497 shares worth $600K. The stake represents 0.15% of the portfolio and ranks #161 among its holdings. This is a return to the name: Perbak Capital Partners previously reported a position in EW as recently as Q3 2025.

Perbak Capital Partners first reported a position in EW in Q3 2025 and has held it in 2 quarters since. The position peaked at $641K in Q3 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Perbak Capital Partners held 7,497 shares of Edwards Lifesciences worth $600K as of Q1 2026.
  • Edwards Lifesciences was a new Perbak Capital Partners position in Q1 2026.
  • Edwards Lifesciences made up 0.15% of Perbak Capital Partners's portfolio in Q1 2026, its #161 holding.
  • Perbak Capital Partners first reported a position in Edwards Lifesciences in Q3 2025 and has held it in 2 quarters since.
  • Perbak Capital Partners's Edwards Lifesciences position peaked at $641K in Q3 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.